A significant decision regarding prostate cancer screening is anticipated to recommend against extending screening tests to a broader male population. The UK National Screening Committee’s three-year evaluation is set to inform ministers today on the potential provision of routine testing for those most vulnerable. The expected decision is to decline the wider implementation of the Prostate Specific Antigen (PSA) test to two specific groups with higher susceptibility to the disease: Black men and men with a family history of prostate cancer.
However, it is likely that the recommendation will suggest inviting a small subset of at-risk men – specifically those with the BRCA gene mutation – for PSA tests. Prostate cancer is the most prevalent cancer in the UK, with 63,000 cases and 12,000 fatalities reported annually. Despite this, unlike breast, bowel, and lung cancer, there is currently no national screening program in place.
Previously, the committee had refrained from endorsing widespread use of the PSA test beyond symptomatic men due to concerns about potential over-diagnosis and unnecessary interventions on men with indolent tumors. Advocates, including Olympic cycling icon Sir Chris Hoy, have been advocating for targeted screening for men with identifiable risk factors, irrespective of symptoms onset.
Prostate Cancer UK has been pushing for targeted screening initiatives for high-risk groups such as Black men, individuals with a family history of the disease, and those with specific BRCA gene variations linked to increased susceptibility.
Recent announcements by former Prime Minister David Cameron, who disclosed his prostate cancer diagnosis, have further fueled calls for a focused screening program. Over 120 Members of Parliament, including former PM Rishi Sunak, have urged Health Secretary Wes Streeting to introduce a targeted screening initiative.
The PSA test measures the levels of a prostate-specific protein in blood samples. Prostate cancer ranks as the second leading cause of male mortality after lung cancer. Studies indicate that mass population screening using PSA tests could potentially reduce mortality rates by 13%, aligning with the impact of existing NHS breast and bowel cancer screening programs.
Nevertheless, the potential benefits of mass screening need to be weighed against the risks of unnecessary treatments like prostate removal or aggressive chemotherapy, which can have adverse effects on quality of life. Alternatives being considered include universal screening of men at a certain age, akin to breast cancer screening in women.
Mr. Streeting has pledged swift action in launching a screening program if endorsed. However, there are speculations that he might override the committee’s decision if it favors expanding prostate screening. Charities stress the importance of evidence-based policies, suggesting a wait for outcomes from ongoing trials like Transform, focused on optimizing prostate cancer screening methods.
Chiara De Biase from Prostate Cancer UK emphasized the need for a scientifically grounded screening program, cautioning against politically driven decisions. Dr. Ian Walker from Cancer Research UK warned against setting a risky precedent by disregarding the committee’s recommendations on screening programs.
For quick access to valued news, select Daily Mirror as a ‘Preferred Source’ on Google News.